(Total Views: 477)
Posted On: 08/12/2020 11:47:29 AM
Post# of 148903
RE: NYT piece yesterday that mentioned leronlimab. https://www.nytimes.com/2020/08/11/magazine/c...Position=1
I wrote this in the comments. I hope they publish it. You can comment too. I am not sure if you need to be a subscriber. Nerdy people read NYT comments!
"This is a fantastic piece. We need to understand how this disease attacks our immune response.Thank you for mentioning leronlimab, a drug made by Cytodyn Inc. The clinical trial for leronlimab in the severe/critical cohort is still underway, but actually, the mild/moderate trial is complete and the company released statistically significant results yesterday. Leronlimab begins working by day 3 and could potentially keep thousands of people out of the ICU. Can you do a follow-up on that?"
I wrote this in the comments. I hope they publish it. You can comment too. I am not sure if you need to be a subscriber. Nerdy people read NYT comments!
"This is a fantastic piece. We need to understand how this disease attacks our immune response.Thank you for mentioning leronlimab, a drug made by Cytodyn Inc. The clinical trial for leronlimab in the severe/critical cohort is still underway, but actually, the mild/moderate trial is complete and the company released statistically significant results yesterday. Leronlimab begins working by day 3 and could potentially keep thousands of people out of the ICU. Can you do a follow-up on that?"
(5)
(0)
Scroll down for more posts ▼